increased mortality, irrespective of the presentation. Substantial patients with STEMI experience no chest pain and are given a low priority score at the triage of emergency department. We aimed to determine the impact of non-chest pain complaint as a presenting symptom on the DTB time and clinical outcomes in patients with STEMI. Methods: A total of 11,417 STEMI patients who underwent primary PCI were derived from the Korea Working Group on Myocardial Infarction from 2005 to 2012 and compared according to typical chest pain or non-chest pain complaint as a presenting symptom. The primary outcomes were 12-month mortality and the composite of major adverse cardiac events (MACE, defined as death, non-fatal myocardial infarction, and revascularization). Results: Compared to patients with typical chest pain (n¼9,948, 87.1%), patients with non-chest pain complaint (n¼1,469, 12.9%) were older, more female, and had higher incidence of hypertension and diabetes, and also had higher incidence of anterior infarct and higher Killip class. The time delay was also significant in doorto-laboratory arrival time (53 vs. 64 min, p<0.001), laboratory arrival-to-balloon (20 vs. 23 min, p<0.001), and the DTB time (75 vs. 89 min, p<0.001). Non-chest pain complaint was an independent determinant of the DTB time both in adjusted models and in multivariate linear regression analysis. Patients with non-chest pain complaint had more in-hospital death (4.1% vs. 11.5%, p<0.001), 12-month mortality (6.5% vs. 16.3%, p<0.001), and the composite of MACE (12.2% vs. 22.5%, p<0.001). Conclusions: The delays in identification of STEMI and reperfusion treatment were greater and associated with worse clinical outcomes in patients with non-chest pain complaint as a presenting symptom. A triage using electrocardiogram should be considered in these patients.
Background: Proximal LAD (pLAD) lesions are associated with increased cardiovascular risk in the setting of acute coronary syndrome (ACS). Surgical versus percutaneous revascularization improves outcomes including mortality in complex stable CAD. However, the impact of different revascularization strategies in ACS patients with pLAD lesions remains unknown. Methods: We performed a post-hoc analysis of patients in the ACUITY trial (n¼13,819) presenting with a critical stenosis of the pLAD who underwent subsequent revascularization with a surgical or percutaneous approach (PCI). Major adverse events comprised of death, myocardial infarction, repeat revascularization, stroke, and bleeding were compared at 30 days and 1-year. Results: Among the 842 patients we studied, revascularization was performed with PCI and coronary artery bypass grafting (CABG) in n¼562 (67%) and n¼280 (33%) respectively. Baseline clinical and angiographic characteristics were well balanced between groups. Patients in the CABG group were more likely to undergo angiography later than PCI (median time first drug-angiography, 43 vs. 4 hours, P<0.01). PCI was associated with an increase rate of revascularization at 1 month and 1 year, without significant difference in other clinical endpoints (Table 1) . Conclusions: Although surgical revascularization of proximal LAD during ACS reduces further revascularization, it does not seem to improve the survival and MI rates at 1-year compared with PCI.
TCT-261
Safety and efficacy of Bivalirudin monotherapy in patients with non-ST segment elevation myocardial infarction undergoing PCI: Results from the ACUITY Study Background: There are limited data on the effects of bivalirudin monotherapy compared to standard antithrombotic therapy (heparin plus glycoprotein IIb/IIIa inhibitor -GPI) on the outcomes of higher -risk acute coronary syndromes (ACS) patients with positive biomarkers on admission. We examined the clinical outcomes among positive biomarker patients undergoing percutaneous coronary intervention (PCI) in the large-scale prospective, randomized ACUITY trial. Methods: The ACUITY trial was a multicenter, randomized trial assessing the safety and efficacy of bivalirudin alone or bivalirudin plus GPI vs. heparin plus GPI among 13,819 patients with moderate and high-risk ACS, 7,789 of whom underwent PCI. The in-hospital and 30-days primary endpoints were composite ischemia (death, MI, or unplanned TVR for ischemia), Non-CABG major bleeding, and net adverse clinical events (NACE¼composite ischemia or major bleeding). Results: A total of 4,728 PCI patients presented with a positive biomarker at the time of admission. Of those, 1,532 were randomized to heparin plus GPI and 1,611 to bivalirudin alone. There were no relevant baseline differences between treatment groups regarding clinical profile, TIMI risk score, antiplatelet medications and DES use. Outcomes by treatment group at 30-days and 1-year are shown in the Background: The impact of left anterior descending artery (LAD) length on left ventricular (LV) remodeling in pts with anterior ST-elevation myocardial infarction (STEMI) has not been fully investigated. Methods: INFUSE-AMI was an open-label, 2Â2 factorial, randomized, multicenter, single-blind evaluation of bolus intralesion abciximab and manual aspiration thrombectomy in pts undergoing bivalirudin supported primary PCI for anterior STEMI. Among 452 enrolled pts, 372 pts with available cardiac magnetic resonance imaging (cMRI) at 30 days were categorized based on coronary angiography as having an LAD that supplied inferior wall myocardium vs. an LAD that terminated at or before the apex. Major adverse cardiac and heart failure events (MACHFE) were death, reinfarction, new onset severe heart failure, or rehospitalisation for heart failure. Results: Because of poor final TIMI flow (0/1) or poor angiography quality, LADs in 19 pts could not be categorized. Among the remaining 353 pts, 206 (58%) had an LAD that wrapped around the apex. Although the time from symptom-onset to first device was significantly shorter in LADs that wrapped around the apex and although the frequency of proximal occlusion location and % infarct mass were similar, LV end diastolic and systolic volumes (assessed by cMRI) at 30 days were larger than in pts with LADs that terminated before the apex (Table) . At 1 year, the rates of MACHFE as well as new onset of severe heart failure and rehospitalisation for heart failure were significantly higher in pts with LADs that wrapped around the apex compared to pts with LADs that terminated before the apex. Conclusions: LAD length is an important determinant of prognosis in pts with anterior STEMI. In these pts, an LAD that wraps around the apex to supply inferior wall myocardium is associated with unfavourable LV remodeling and subsequent heart failure.
TCT-264
The Background: Long term prognosis of left ventricular (LV) systolic function was well known but LV diastolic function in patients with ST segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI) was not studied well. Methods: A consecutive 325 patients treated with primary PCI. Transthoracic echocardiography was performed within 24 hour after PCI and at 12 months followup. The indices of LV systolic function (LV ejection fraction-EF, wall motion score index-WMSI), LV diastolic function (The ratio of the transmitral and myocardial early diastolic velocities (E/Em)) and LV dimension were measured. Results: At 12 month follow-up, we observed the significant improvement of LVEF (49.1AE9.8 % to 53.9AE10.3 %, p < 0.01), the decrease of WMSI (1.42AE0.36 to 1.33AE0.37, p < 0.001) and significant decrease in LV end diastolic dimension(52.1 AE 6.6 to 49.8AE6.8). But, there was no significant difference but numerically worsening LV diastolic function (E/Em 12.7AE5.4 to 13.6 AE7.8, p¼0.38). Conclusions: The LV systolic function was improved but LV diastolic function was not improved after STEMI treated with primary PCI. 
